Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open Label, Two Parts Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Glioma

Next Previous
Search
Trial Profile

A Phase 2, Multicenter, Open Label, Two Parts Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant Glioma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Safusidenib (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms G203
  • Sponsors AnHeart Therapeutics

    • Most Recent Events

    • 18 Nov 2024 Status changed from recruiting to active, no longer recruiting.
    • 10 Apr 2024 According to a Nuvation Bio media release, AnHeart Therapeutics has been acquired by Nuvation Bio and AnHeart is now a wholly-owned subsidiary of Nuvation Bio.
    • 07 Sep 2023 According to a AnHeart Therapeutics media release, currently patients are being enrolled in the United States, with expansion to other countries planned for Part 2 of the trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top